FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.

The preliminary safety and efficacy data from the Phase 2 KUNPENG clinical trial, evaluating vebreltinib in patients in China with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring c-MET alterations will be presented by Beijing Pearl, Apollomics’ partner in China in a poster presentation session. The poster will include data from patients with METex14 mutation (Cohort 1) from the Phase 2, open-label, multicenter and multi-cohort study.

"Vebreltinib continues to yield compelling data, reinforcing its potential as a vital treatment option for patients with challenging-to-treat cancers driven by c-MET alterations,” said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics. “We're excited to share these updates with the global oncology community at ESMO.”

In addition, as part of a real-life cohort analysis of targeted therapy for subjects with recurrent glioblastoma (GBM), preliminary data on vebreltinib from the APL-101-01 SPARTA study will be part of a mini-oral presentation.

Presentation materials will be available on the Apollomics website following the presentations at ESMO: https://ir.apollomicsinc.com/news-events/presentations.

Presentation Title: Preliminary Results of Phase II KUNPENG Study of Vebreltinib in Patients (Pts) with Advanced NSCLC Harboring c-MET AlterationsSpeaker: Jin-Ji Yang from the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.Abstract Number: #1379PSession: NSCLC, metastaticDate: Monday, October 23 from 12:00-13:00 CEST

Presentation Title: Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy)Speaker: Giulia Cerretti (Veneto Institute of Oncology, Padova, Italy)Presentation Number: 502MOSession: Mini Oral sessionDate: Saturday, October 21 from 10:15 – 11:45 CEST